Project Grant HT94252510648
Award Date
8/1/25
Completion Date
7/31/28
Dollars Obligated
$5.1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Minneapolis, MN 55414, USA
Similar Awards
The University of Minnesota was awarded a $479,946 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project from August 1, 2023 to July 31, 2026 to leverage a precision medicine platform to predict novel therapies for malignant peripheral nerve sheath tumors. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,848,000.00 to the Regents of the University of Minnesota to conduct research on therapeutic targeting of aberrant mRNA polyadenylation in lethal prostate cancer. The research aims to transform healthcare for military service members, veterans, and the broader public by advancing innovative biomedical investigations in this critical medical domain. The...
The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $1,243,750 Project Grant to the Regents of the University of Minnesota, doing business as the Office of Sponsored Projects Administration, to develop allogeneic, multiplex base-edited, dual-targeted gamma delta CAR-T cell therapies for the treatment of metastatic castration-resistant prostate cancer. This 3-year award, with a project period from Sep 30, 2024 to Sep 29, 2027, will...
The Regents of the University of Minnesota received a $515,187 Project Grant award from the Defense Health Agency to conduct research titled "Leveraging Reactivation of Tissue-Resident Memory T Cells in the Tumor Microenvironment for Oncolytic Virotherapy." The grant is part of the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care through innovative medical...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,155,000 Project Grant to the Regents of the University of Minnesota to evaluate prostate cancer patient natural killer cell function across racial backgrounds and address functional disparities with trispecific killer engagers. The award, which runs from June 1, 2025 to May 31, 2029, supports advanced biomedical research aimed at transforming healthcare for military service members, veterans,...
The University of Minnesota, through its Office of Sponsored Projects Administration, was awarded a $1,521,386 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to engage the immune system to kill sarcoma through a comparative oncology approach. The 3-year grant, which began on July 15, 2023 and will be completed by July 14, 2026, supports basic, applied, and advanced biomedical research to transform healthcare for service...
This Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $1,618,500.00 to the Regents of the University of Minnesota to support research aimed at "Targeting eIF4F Complex-Driven Translation of Oncogenic mRNAs in CRPC". The 3-year award, which runs from June 1, 2025 to May 31, 2028, will fund advanced biomedical research focused on innovative solutions to transform healthcare for military service...
The University of Minnesota has been awarded a $665,335 Project Grant from the U.S. Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant, awarded on July 1, 2024, will fund research to investigate "Trapping Inhibitory Signals in Synergy with Cytokine Signaling to Maximize NK Cell Immunotherapy in Ovarian Cancer." The project, set to run through June 30, 2028, aims to develop new immunotherapy approaches for treating...
The Regents of the University of Minnesota was awarded a $1,202,776 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from July 1, 2023 to June 30, 2027 to map elements of DNA architecture responsible for malignant transformation in craniospinal sarcoma. Through this award, the University of Minnesota will conduct biomedical research to identify medical solutions for battlefield...
This federal Project Grant award from the Department of the Army Medical Command (CFDA 12.420 - Military Medical Research and Development) provides $1,348,041.00 to the Regents of the University of Minnesota to develop a RET-specific proteomic assay from circulating tumor cells in lethal prostate cancer. The award began on Mar 1, 2024 and is scheduled for completion by Feb 28, 2027. This research aims to transform health care for military service members and the general public through innovative...